About 200 reports

  • CHAPTER IV EMERGING PHARMACEUTICALS PRODUCTION AND DEMAND
  • Chapter IV

This study focuses on China’s Emerging Pharmaceuticals industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s...

  • Pharmaceutical
  • Bristol-Myers Squibb Company
  • CSPC Pharmaceutical Group Limited
  • Tasly Pharmaceutical Co., Ltd.
  • Zhejiang Conba Pharmaceutical Co., Ltd.
  • Cardiovascular Disease Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006-2017
  • Co-development Deals, 2017 Part 1

In this context, a first-in-class target is one that is not acted on by any product on the market in any indication across the pharmaceutical industry, and a first-inclass product is one that acts on at least one of these targets.

  • Cardiovascular Disease
  • Chronic Disease
  • Pathology
  • Pharmaceutical
  • Bristol-Myers Squibb Company
  • HEPATITIS C THERAPEUTICS MARKET, GLOBAL, PIPELINE PRODUCTS, 2016 (PART 2)
  • HEPATITIS C THERAPEUTICS MARKET, GLOBAL, PIPELINE PRODUCTS, 2016 (PART 3)

IN THIS CONTEXT, A FIRST-IN-CLASS TARGET IS ONE THAT IS NOT ACTED ON BY ANY PRODUCT ON THE MARKET IN ANY INDICATION ACROSS THE PHARMACEUTICAL INDUSTRY, AND A FIRST-IN-CLASS PRODUCT IS ONE THAT ACTS ON AT LEAST ONE OF THESE TARGETS.

  • Hepatitis
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Hematological Cancers Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
  • for Co-development Deals Valued above $100m

Pharma Mar, S. A.

  • Leukemia
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • Novartis AG
  • TOP 20 PHARMACEUTICALS COMPANIES: REVENUE
  • TOP 20 PHARMACEUTICALS COMPANIES: REVENUE GROWTH

Pharmaceuticals - Global Industry Leaders: Top 20 Company Financials Chartbooks Summary In recent years technological innovation has revolutionized almost all markets and industries. This combined with growing political uncertainty, slumps in consumer demand and shifting growth rates in developing economies has thrust...

  • Pharmaceutical
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers
  • Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Programs in Active Development Involved

Figure ##: Overall Pharmaceutical Industry, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Over the past decade the pharmaceutical industry has witnessed a profound change in the technological, clinical and commercial landscape acro

  • Leukemia
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • ASTRAZENECA ACQUIRED OMTHERA PHARMACEUTICALS
  • Cardiovascular Drugs Market Key Mergers And Acquisitions

Cardiovascular drugs market covers the drugs used to treat conditions that affect the heart or blood vessels. These conditions include heart stroke, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Some of the major cardiovascular...

  • Cardiovascular Drug
  • Pharmaceutical
  • World
  • Market Size
  • Bristol-Myers Squibb Company
  • Big Pharma sales, by company ($bn), 2014-24
  • Big Pharma product launch, by brand ($m), 2010-19

Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on highperforming markets This report explores and visualizes market dynamics in the Big Pharma peer set out to 2024, using in-house sales forecasts By delving deeper into drivers of strategy,...

  • Pharmaceutical
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • MAB PIPELINE BY COMPANY AND STAGE OF DEVELOPMENT
  • 6.3.3 COMPANIES BY MAB TYPE

There are currently eight mAb products in development by the top ## pharmaceuticals companies at Pre-registration, and one at Phase III.

  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • 7.2.4 TABLE FOR CO-DEVELOPMENT DEALS WITH DISCLOSED VALUES
  • GENETIC DISORDERS MARKET, GLOBAL, FORECAST REVENUE BY COMPANY, 2016-2023

Indian Journal of Pediatrics; ##(##): ##-## GW Pharmaceuticals (2017).

  • Clinical Trial
  • Genetic Disorder
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • CARDIOVASCULAR DISEASE DRUGS MARKET, GLOBAL, FORECAST REVENUES BY COMPANY, 2016-2023
  • 4.4.5 ASSESSMENT OF KEY PIPELINE PRODUCTS

There is a strong presence among the top-## pharma companies in the pipeline, with ## of these companies having at least one CVD product in active development.

  • Cardiovascular Disease
  • Chronic Disease
  • Pharmaceutical
  • Market Size
  • Bristol-Myers Squibb Company
  • BRISTOL-MYERS SQUIBB COMPANY

GSK has started with its set up of one of the largest Indian tablet manufacturing pharmaceutical factory of around ## per cent of its income. development.

  • Hepatitis
  • Hepatitis Treatment
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • Biologics Market Competitive Landscape

ABBVIE OPERATES THROUGH ONLY ONE DIVISION - PHARMACEUTICAL PRODUCT.

  • Monoclonal Antibody
  • Pharmaceutical
  • Vaccine
  • Market Segment
  • Bristol-Myers Squibb Company
  • BRISTOL MYERS SQUIBB COMPANY: KEY FACTS
  • LEADING COMPANIES

TABLE ##: ALMIRALL S. A. : KEY FACTS Almirall operates in one segment: pharmaceuticals.

  • OTC
  • Pharmaceutical
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • BRISTOL-MYERS SQUIBB: REVENUE OF REYATAZ 2012-2014 ($ BILLIONS)
  • STRATEGIC ALLIANCES

Elvitegravir is an inhibitor of HIV-## integrase.

  • Antiviral
  • HIV AIDS
  • Pharmaceutical
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • 3.3.2 BIOMAB EGFR (NIMOTUZUMAB) - BIOCON/BIOTECH PHARMACEUTICAL CO.
  • 8 Deals and Strategic Consolidations

Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market Summary Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is growing. The term head and neck cancer (HNC) refers...

  • Chemotherapy
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • NSCLC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017
  • 9 Appendix

Plinabulin has demonstrated synergistic effects with PD-## antibodies and PD-## and CTLA-## antibodies, and has exhibited a broad spectrum of immune- ##. ##. ## PLINABULIN - BEYONDSPRING PHARMA enhancing effects that are complimentary to PD-## inhibitors in preclinical st

  • Lung Cancer
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company
  • Major Collaborations in Renal Cell Carcinoma
  • III. RCC Drug Pipeline by Molecule Types

RCC Market Patent Trend by Top Inventors Merck ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Pfizer ## ## ## ## ## ## ## ## ## ## ## ## ## ## Roche ## ## ## ## ## ## ## ## ## ## ## ## ## ## NIH ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Genentech ## ## ## ## ## ## ## ## ##

  • Cancer
  • Pharmaceutical
  • Renal Cancer
  • Therapy
  • Bristol-Myers Squibb Company
  • Major Prostate Cancer Treatment Drugs Producer Sales
  • III

China’s demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export,...

  • Hormone
  • Pharmaceutical
  • Prostate Cancer
  • AstraZeneca Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb Company
  • MARKET SHARE ANALYSIS 2015
  • TOP-VENDOR OFFERINGS

The financial year of Takeda Pharmaceuticals is from April ## to March ##.

  • Cancer Immunotherapy
  • Pharmaceutical
  • Therapy
  • Market Size
  • Bristol-Myers Squibb Company
  • Androgen Receptor Antagonist Major Producer and Their Market Share (million yuan)
  • Cyproterone Acetate Major Producer and Their Market

This study focuses on China’s Prostate Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of...

  • Hormone
  • Pharmaceutical
  • Prostate Cancer
  • AstraZeneca Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb Company

Cerulean Pharma Inc ##.

  • Pharmaceutical
  • Renal Cancer
  • Targeted Therapy
  • Bristol-Myers Squibb Company
  • Exelixis, Inc.
  • UROLOGIC ONCOLOGY THERAPEUTICS MARKET, GLOBAL, FORECAST REVENUES BY
  • Company Analysis and Positioning

Pharma Times.

  • Pharmaceutical
  • Therapy
  • Urology
  • World
  • Bristol-Myers Squibb Company
  • PHARMACEUTICAL
  • BIOSTAR PHARMACEUTICALS

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest...

  • Pharmaceutical
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • RA Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
  • RA Therapeutics Market, Global, All Pipeline Products, Phase II, 2016

In 2012, Abbott was restructured into two companies, one of which specializes in pharmaceuticals (AbbVie), while the other specializes in medical products and retained the Abbot name.

  • Clinical Trial
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • Bristol-Myers Squibb

Rating indicates the level of growth opportunities and the green arrows point to the category with high opportunities Impact: ## Low; ## High Assessment The drug contains gemcitabine as its active pharmaceutical ingredient.

  • Bladder Cancer
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Major Producers Output in 2017(Billion Yuan)
  • Cardiovascular Drugs Producers Output and Their

China’s demand for Cardiovascular Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...

  • Cardiovascular Drug
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • Tasly Pharmaceutical Co., Ltd.
  • Respiratory Complications Therapeutics Market, Global, Companies by Compound
  • 7.2.4 Co-development Deals Valued Above $100m

It maintains a comprehensive database of ##, ## pharmaceutical companies.

  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • Bristol-Myers Squibb Company
  • Vendor landscape
  • Market landscape

In this condition individuals experience one or more depressive episodes followed by at least one episode of hypomania.

  • Bipolar Disorder
  • Pharmaceutical
  • Therapy
  • Allergan plc
  • Bristol-Myers Squibb Company
  • OTHER PROMINENT VENDORS
  • PHARMAMAR COMMENCED A NEW PHASE III TRIAL FOR THE TREATMENT OF SCLC IN SPAIN

February 2016: OSE Pharma initiates the Atalante ## Phase III trial designed to evaluate Tedopi for the potential treatment of advanced NSCLC.

  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company